The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Hepatitis C

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Hepatitis C


Psychiatry related information on Hepatitis C


High impact information on Hepatitis C

  • RESULTS: At the completion of treatment, serum levels of hepatitis C virus (HCV) RNA were undetectable in 141 of the 173 patients who were treated with interferon and ribavirin and in 80 of the 172 patients who were treated with interferon alone (82 percent vs. 47 percent, P<0.001) [11].
  • During replication of hepatitis C virus (HCV), the final steps of polyprotein processing are performed by a viral proteinase located in the N-terminal one-third of nonstructural protein 3 [12].
  • We used three markers to detect hepatitis C virus (HCV) infection in stored samples of serum: antibody to HCV (anti-HCV) detected by second-generation serologic assays; HCV RNA detected by polymerase-chain-reaction assay; and antibody to HCV antigen (anti-HCVAg) detected by fluorescent-antibody-blocking assay [13].
  • Here we show that the tetraspanin CD81, a putative receptor for hepatitis C virus, is required on hepatocytes for human Plasmodium falciparum and rodent Plasmodium yoelii sporozoite infectivity [14].
  • Hepatitis C virus, the E2 envelope protein, and alpha-interferon resistance [15].

Chemical compound and disease context of Hepatitis C


Biological context of Hepatitis C


Anatomical context of Hepatitis C

  • Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions [26].
  • Analysis of the peripheral blood T cell proliferative response to core, E1, E2, NS3, NS4, and NS5 recombinant antigens and synthetic peptides showed that responses to all hepatitis C virus antigens, except E1, were significantly more vigorous and more frequently detectable in patients who normalized transaminase levels than in those who did not [27].
  • Suppression or overexpression of La protein and polypyrimidine tract binding protein in RCF-26 significantly changed hepatitis C virus internal ribosome entry site activity [28].
  • The CD11c-enriched dendritic cell population obtained from the spleen was transduced in vitro with recombinant hepatitis C virus core and nonstructural 5 proteins by using macromolecular-based protein delivery [29].
  • We reported that hepatitis C virus (HCV) core and nonstructural 3 (NS3) proteins activate inflammatory pathways in monocytes [30].

Gene context of Hepatitis C


Analytical, diagnostic and therapeutic context of Hepatitis C


  1. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Crotty, S., Maag, D., Arnold, J.J., Zhong, W., Lau, J.Y., Hong, Z., Andino, R., Cameron, C.E. Nat. Med. (2000) [Pubmed]
  2. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. Yoshida, T., Hanada, T., Tokuhisa, T., Kosai, K., Sata, M., Kohara, M., Yoshimura, A. J. Exp. Med. (2002) [Pubmed]
  3. The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. Kew, M.C., Yu, M.C., Kedda, M.A., Coppin, A., Sarkin, A., Hodkinson, J. Gastroenterology (1997) [Pubmed]
  4. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Fong, T.L., Valinluck, B., Govindarajan, S., Charboneau, F., Adkins, R.H., Redeker, A.G. Gastroenterology (1994) [Pubmed]
  5. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Poynard, T., McHutchison, J., Manns, M., Trepo, C., Lindsay, K., Goodman, Z., Ling, M.H., Albrecht, J. Gastroenterology (2002) [Pubmed]
  6. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Poynard, T., Marcellin, P., Lee, S.S., Niederau, C., Minuk, G.S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., Albrecht, J. Lancet (1998) [Pubmed]
  7. Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Fargion, S., Fracanzani, A.L., Piperno, A., Braga, M., D'Alba, R., Ronchi, G., Fiorelli, G. Hepatology (1994) [Pubmed]
  8. Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma--its relationship to alcohol drinking and the age of transfusion. Noda, K., Yoshihara, H., Suzuki, K., Yamada, Y., Kasahara, A., Hayashi, N., Fusamoto, H., Kamada, T. Alcohol. Clin. Exp. Res. (1996) [Pubmed]
  9. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Dolan, K.A., Shearer, J., White, B., Zhou, J., Kaldor, J., Wodak, A.D. Addiction (2005) [Pubmed]
  10. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Raison, C.L., Broadwell, S.D., Borisov, A.S., Manatunga, A.K., Capuron, L., Woolwine, B.J., Jacobson, I.M., Nemeroff, C.B., Miller, A.H. Brain Behav. Immun. (2005) [Pubmed]
  11. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Davis, G.L., Esteban-Mur, R., Rustgi, V., Hoefs, J., Gordon, S.C., Trepo, C., Shiffman, M.L., Zeuzem, S., Craxi, A., Ling, M.H., Albrecht, J. N. Engl. J. Med. (1998) [Pubmed]
  12. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Love, R.A., Parge, H.E., Wickersham, J.A., Hostomsky, Z., Habuka, N., Moomaw, E.W., Adachi, T., Hostomska, Z. Cell (1996) [Pubmed]
  13. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. Alter, M.J., Margolis, H.S., Krawczynski, K., Judson, F.N., Mares, A., Alexander, W.J., Hu, P.Y., Miller, J.K., Gerber, M.A., Sampliner, R.E. N. Engl. J. Med. (1992) [Pubmed]
  14. Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity. Silvie, O., Rubinstein, E., Franetich, J.F., Prenant, M., Belnoue, E., Rénia, L., Hannoun, L., Eling, W., Levy, S., Boucheix, C., Mazier, D. Nat. Med. (2003) [Pubmed]
  15. Hepatitis C virus, the E2 envelope protein, and alpha-interferon resistance. Abid, K., Quadri, R., Negro, F. Science (2000) [Pubmed]
  16. Hepatitis C virus infection and risk of hepatocellular carcinoma among Japanese: possible role of type 1b (II) infection. Tanaka, K., Ikematsu, H., Hirohata, T., Kashiwagi, S. J. Natl. Cancer Inst. (1996) [Pubmed]
  17. Detection of genomic and intermediate replicative strands of hepatitis C virus in liver tissue by in situ hybridization. Nouri Aria, K.T., Sallie, R., Sangar, D., Alexander, G.J., Smith, H., Byrne, J., Portmann, B., Eddleston, A.L., Williams, R. J. Clin. Invest. (1993) [Pubmed]
  18. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Hinrichsen, H., Benhamou, Y., Wedemeyer, H., Reiser, M., Sentjens, R.E., Calleja, J.L., Forns, X., Erhardt, A., Crönlein, J., Chaves, R.L., Yong, C.L., Nehmiz, G., Steinmann, G.G. Gastroenterology (2004) [Pubmed]
  19. Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. Kumar, U., Monjardino, J., Thomas, H.C. Gastroenterology (1994) [Pubmed]
  20. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Frank, C., Mohamed, M.K., Strickland, G.T., Lavanchy, D., Arthur, R.R., Magder, L.S., El Khoby, T., Abdel-Wahab, Y., Aly Ohn, E.S., Anwar, W., Sallam, I. Lancet (2000) [Pubmed]
  21. Cyclophilin B escorts the hepatitis C virus RNA polymerase: a viral achilles heel? Heitman, J., Cullen, B.R. Mol. Cell (2005) [Pubmed]
  22. Real-time detection system for quantification of hepatitis C virus genome. Takeuchi, T., Katsume, A., Tanaka, T., Abe, A., Inoue, K., Tsukiyama-Kohara, K., Kawaguchi, R., Tanaka, S., Kohara, M. Gastroenterology (1999) [Pubmed]
  23. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Nakagawa, M., Sakamoto, N., Tanabe, Y., Koyama, T., Itsui, Y., Takeda, Y., Chen, C.H., Kakinuma, S., Oooka, S., Maekawa, S., Enomoto, N., Watanabe, M. Gastroenterology (2005) [Pubmed]
  24. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Okuda, M., Li, K., Beard, M.R., Showalter, L.A., Scholle, F., Lemon, S.M., Weinman, S.A. Gastroenterology (2002) [Pubmed]
  25. Viral error catastrophe by mutagenic nucleosides. Anderson, J.P., Daifuku, R., Loeb, L.A. Annu. Rev. Microbiol. (2004) [Pubmed]
  26. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. Tseng, C.T., Klimpel, G.R. J. Exp. Med. (2002) [Pubmed]
  27. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. Missale, G., Bertoni, R., Lamonaca, V., Valli, A., Massari, M., Mori, C., Rumi, M.G., Houghton, M., Fiaccadori, F., Ferrari, C. J. Clin. Invest. (1996) [Pubmed]
  28. La protein is a potent regulator of replication of hepatitis C virus in patients with chronic hepatitis C through internal ribosomal entry site-directed translation. Honda, M., Shimazaki, T., Kaneko, S. Gastroenterology (2005) [Pubmed]
  29. Vaccination with protein-transduced dendritic cells elicits a sustained response to hepatitis C viral antigens. Kuzushita, N., Gregory, S.H., Monti, N.A., Carlson, R., Gehring, S., Wands, J.R. Gastroenterology (2006) [Pubmed]
  30. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Dolganiuc, A., Oak, S., Kodys, K., Golenbock, D.T., Finberg, R.W., Kurt-Jones, E., Szabo, G. Gastroenterology (2004) [Pubmed]
  31. Binding of hepatitis C virus to CD81. Pileri, P., Uematsu, Y., Campagnoli, S., Galli, G., Falugi, F., Petracca, R., Weiner, A.J., Houghton, M., Rosa, D., Grandi, G., Abrignani, S. Science (1998) [Pubmed]
  32. Translational repression by a novel partner of human poly(A) binding protein, Paip2. Khaleghpour, K., Svitkin, Y.V., Craig, A.W., DeMaria, C.T., Deo, R.C., Burley, S.K., Sonenberg, N. Mol. Cell (2001) [Pubmed]
  33. Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Tung, B.Y., Emond, M.J., Bronner, M.P., Raaka, S.D., Cotler, S.J., Kowdley, K.V. Gastroenterology (2003) [Pubmed]
  34. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Cramp, M.E., Rossol, S., Chokshi, S., Carucci, P., Williams, R., Naoumov, N.V. Gastroenterology (2000) [Pubmed]
  35. Specificity of the hepatitis C virus antibody ELISA in patients with hepatocellular carcinoma. Colombo, M., Grazia Rumi, M., Romeo, R., Sangiovanni, A. J. Natl. Cancer Inst. (1990) [Pubmed]
  36. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Féray, C., Caccamo, L., Alexander, G.J., Ducot, B., Gugenheim, J., Casanovas, T., Loinaz, C., Gigou, M., Burra, P., Barkholt, L., Esteban, R., Bizollon, T., Lerut, J., Minello-Franza, A., Bernard, P.H., Nachbaur, K., Botta-Fridlund, D., Bismuth, H., Schalm, S.W., Samuel, D. Gastroenterology (1999) [Pubmed]
  37. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Samuel, D., Bizollon, T., Feray, C., Roche, B., Ahmed, S.N., Lemonnier, C., Cohard, M., Reynes, M., Chevallier, M., Ducerf, C., Baulieux, J., Geffner, M., Albrecht, J.K., Bismuth, H., Trepo, C. Gastroenterology (2003) [Pubmed]
  38. Posttransfusion hepatitis revisited by hepatitis C antibody assays and polymerase chain reaction. Wang, J.T., Wang, T.H., Sheu, J.C., Lin, J.T., Wang, C.Y., Chen, D.S. Gastroenterology (1992) [Pubmed]
  39. Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Serfaty, L., Chazouillères, O., Pawlotsky, J.M., Andreani, T., Pellet, C., Poupon, R. Gastroenterology (1996) [Pubmed]
WikiGenes - Universities